Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma

被引:157
作者
Bateman, Eric D. [2 ]
Kornmann, Oliver [3 ]
Schmidt, Peter [4 ]
Pivovarova, Anna [4 ]
Engel, Michael [4 ]
Fabbri, Leonardo M. [1 ]
机构
[1] Univ Modena & Reggio Emilia, Sect Resp Dis, Dept Oncol Haematol & Resp Dis, Policlin Modena, I-41124 Modena, Italy
[2] Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa
[3] IKF Clin Res Ctr Resp Med, Frankfurt, Germany
[4] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
关键词
Arginine/arginine genotype; beta(2)-agonist receptor; muscarinic receptor; airway obstruction; bronchodilators; ACTING BETA-AGONISTS; FLUTICASONE; BROMIDE; THERAPY; POLYMORPHISMS; COMBINATION; PREVENTION; SAFETY; ADULTS; ADRB2;
D O I
10.1016/j.jaci.2011.06.004
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: The efficacy and safety of inhaled long-acting beta(2)-adrenergic agonists in asthmatic patients with the B16-Arg/Arg genotype has been questioned, and the use of antimuscarinics has been proposed as an alternative in patients whose symptoms are not controlled by inhaled corticosteroids (ICSs). Objective: We compared the efficacy and safety of the long-acting anticholinergic tiotropium with salmeterol and placebo added to an ICS in B16-Arg/Arg patients with asthma that was not controlled by ICSs alone. Methods: In a double-blind, double-dummy, placebo-controlled trial, after a 4-week run-in period with 50 mu g of twice-daily salmeterol administered through a metered-dose inhaler, 388 asthmatic patients were randomized 1:1:1 to 16 weeks of treatment with 5 mu g of Respimat tiotropium administered daily in the evening, 50 mu g of salmeterol administered twice daily through a metered-dose inhaler, or placebo. Patients aged 18 to 67 years demonstrated reversibility to bronchodilators, and their symptoms were uncontrolled by regular ICSs (400-1000 mg of budesonide/equivalent). ICS regimens were maintained throughout the trial. The mean weekly morning peak expiratory flow (PEF) before randomization was 358 +/- 115.7 L/min (range, 80.3-733.0 L/min). Results: Changes in weekly PEF from the last week of the run-in period to the last week of treatment (primary end point: change in PEF) were -3.9 +/- 4.87 L/min (n = 128) for tiotropium and -3.2 +/- 4.64 L/min (n = 134) for salmeterol, and these were superior to placebo (-24.6 +/- 4.84 L/min, n = 125, P < .05). Tiotropium was noninferior to salmeterol (estimated difference, -0.78 L/min [95% CI, -13.096 to 11.53]; P = .002; alpha = .025, 1-sided; noninferiority, 20 L/min). Tiotropium and salmeterol were numerically superior to placebo in some patient-reported secondary outcomes. Adverse events were comparable across treatments. Conclusion: Tiotropium was more effective than placebo and as effective as salmeterol in maintaining improved lung function in B16-Arg/Arg patients with moderate persistent asthma. Safety profiles were comparable. (J Allergy Clin Immunol 2011;128:315-22.)
引用
收藏
页码:315 / 322
页数:8
相关论文
共 36 条
[1]  
[Anonymous], 1995, Global Strategy for Asthma Management and Prevention
[2]   Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study [J].
Bateman, E. D. ;
Bousquet, J. ;
Busse, W. W. ;
Clark, T. J. H. ;
Gul, N. ;
Gibbs, M. ;
Pedersen, S. .
ALLERGY, 2008, 63 (07) :932-938
[3]   Global strategy for asthma management and prevention: GINA executive summary [J].
Bateman, E. D. ;
Hurd, S. S. ;
Barnes, P. J. ;
Bousquet, J. ;
Drazen, J. M. ;
FitzGerald, M. ;
Gibson, P. ;
Ohta, K. ;
O'Byrne, P. ;
Pedersen, S. E. ;
Pizzichini, E. ;
Sullivan, S. D. ;
Wenzel, S. E. ;
Zar, H. J. .
EUROPEAN RESPIRATORY JOURNAL, 2008, 31 (01) :143-178
[4]   A one-year trial of tiotropium Respimat® plus usual therapy in COPD patients [J].
Bateman, E. D. ;
Tashkin, D. ;
Siafakas, N. ;
Dahl, R. ;
Towse, L. ;
Massey, D. ;
Pavia, D. ;
Zhong, N. S. .
RESPIRATORY MEDICINE, 2010, 104 (10) :1460-1472
[5]   Alternative mechanisms for tiotropium [J].
Bateman, E. D. ;
Rennard, S. ;
Barnes, P. J. ;
Dicpinigaitis, P. V. ;
Gosens, R. ;
Gross, N. J. ;
Nadel, J. A. ;
Pfeifer, M. ;
Racke, K. ;
Rabe, K. F. ;
Rubin, B. K. ;
Welte, T. ;
Wessler, I. .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2009, 22 (06) :533-542
[6]   Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down [J].
Bateman, ED ;
Jacques, L ;
Goldfrad, C ;
Atienza, T ;
Mihaescu, T ;
Duggan, M .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (03) :563-570
[7]  
Bateman Eric, 2010, Int J Chron Obstruct Pulmon Dis, V5, P197
[8]   Safety of long-acting β-agonists: urgent need to clear the air remains [J].
Beasley, R. ;
Martinez, F. D. ;
Hackshaw, A. ;
Rabe, K. F. ;
Sterk, P. J. ;
Djukanovic, R. .
EUROPEAN RESPIRATORY JOURNAL, 2009, 33 (01) :3-5
[9]   Effect of ADRB2 polymorphisms on response to longacting β2-agonist therapy:: a pharmacogenetic analysis of two randomised studies [J].
Bleecker, Eugene R. ;
Postma, Dirkje S. ;
Lawrance, Rachael M. ;
Meyers, Deborah A. ;
Ambrose, Helen J. ;
Goldman, Mitch .
LANCET, 2007, 370 (9605) :2118-2125
[10]  
Bleecker ER, 2010, AM J RESP CRIT CARE, V181, P676, DOI [10.1164/rccm.200809-1511OC, 10.1164/200809-1511OC]